AVI BioPharma, Inc. (AVII) Reports Solid Q4 Results; Guides FY12
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Financial Fact:
Net income (loss) and comprehensive income (loss): -56.74M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Net income (loss) and comprehensive income (loss): -56.74M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q4 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.03 million.
Sees FY2012 revenue of $40-$50 million, versus the consensus of $54.14 million. Sees a loss from operations of $30-$35 million.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
Sees FY2012 revenue of $40-$50 million, versus the consensus of $54.14 million. Sees a loss from operations of $30-$35 million.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
- Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
